Achieve Life Sciences (NASDAQ:ACHV) Now Covered by Rodman & Renshaw

Equities research analysts at Rodman & Renshaw began coverage on shares of Achieve Life Sciences (NASDAQ:ACHV) in a report released on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $12.00 price target on the biopharmaceutical company’s stock. Rodman & Renshaw’s price target suggests a potential upside of 164.90% from the stock’s current price.

A number of other equities analysts also recently issued reports on ACHV. Oppenheimer reaffirmed an “outperform” rating and set a $11.00 price target on shares of Achieve Life Sciences in a research report on Thursday, August 15th. Raymond James began coverage on Achieve Life Sciences in a research report on Friday, September 27th. They set a “strong-buy” rating and a $20.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $14.80.

Achieve Life Sciences Stock Down 2.6 %

Shares of NASDAQ ACHV opened at $4.53 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. The firm has a market capitalization of $155.79 million, a price-to-earnings ratio of -4.01 and a beta of 1.57. The stock has a 50 day moving average price of $4.72 and a 200 day moving average price of $4.77. Achieve Life Sciences has a 52-week low of $3.03 and a 52-week high of $5.98.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.10). During the same period in the prior year, the company earned ($0.34) EPS. Sell-side analysts expect that Achieve Life Sciences will post -1.17 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of Achieve Life Sciences during the 3rd quarter worth about $54,000. Virtu Financial LLC acquired a new position in shares of Achieve Life Sciences during the 1st quarter worth about $59,000. The Manufacturers Life Insurance Company acquired a new position in shares of Achieve Life Sciences during the 2nd quarter worth about $69,000. MetLife Investment Management LLC raised its position in shares of Achieve Life Sciences by 65.6% during the 3rd quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,939 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Achieve Life Sciences by 134.2% in the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 14,360 shares during the last quarter. Institutional investors and hedge funds own 33.52% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.